Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy

L. Lit, Frank R Sharp, Michelle L Apperson, Da Liu, W. L. Walker, I. Liao, H. Xu, Bradley Ander, B. Wong

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects. As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients. Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents nave to corticosteroids (DMD). The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups. Affymetrix U133 Plus 2.0 expression microarrays were used to evaluate mRNA expression. Expression of 524 probes changed with corticosteroids, including genes in iron trafficking and the chondroitin sulfate biosynthesis pathway. Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism. These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.

Original languageEnglish (US)
Pages (from-to)411-418
Number of pages8
JournalPharmacogenomics Journal
Issue number6
StatePublished - Dec 2009


  • Corticosteroid
  • Duchenne muscular dystrophy
  • Gene expression
  • Microarray
  • Prednisone

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics


Dive into the research topics of 'Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy'. Together they form a unique fingerprint.

Cite this